News stories about Affimed (NASDAQ:AFMD) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Affimed earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.0502393378178 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- BMO Capital Markets Trims Affimed (AFMD) Target Price to $4.00 (americanbankingnews.com)
- Affimed Therapeutics (AFMD) CEO Adi Hoess on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates (finance.yahoo.com)
- Affimed (AFMD) Set to Announce Earnings on Wednesday (americanbankingnews.com)
Shares of NASDAQ:AFMD remained flat at $$1.60 during midday trading on Friday. The company had a trading volume of 534,695 shares, compared to its average volume of 185,715. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.57 and a current ratio of 5.36. Affimed has a 12 month low of $1.15 and a 12 month high of $2.85. The company has a market cap of $99.82 million, a price-to-earnings ratio of -2.05 and a beta of 2.35.
Affimed (NASDAQ:AFMD) last released its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). The company had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.54 million. Affimed had a negative return on equity of 74.04% and a negative net margin of 1,723.04%. sell-side analysts predict that Affimed will post -0.69 EPS for the current fiscal year.
Several analysts have issued reports on the company. Zacks Investment Research lowered Affimed from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. ValuEngine upgraded Affimed from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Finally, BMO Capital Markets lowered their target price on Affimed from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Recommended Story: Trading Strategy
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.